Global Calcium Antagonists Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Calcium Antagonists Market Research Report 2024
Calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients. Calcium channel blockers are also frequently used to alter heart rate (especially from atrial fibrillation), to prevent peripheral and cerebral vasospasm, and to reduce chest pain caused by angina pectoris.
N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents.
CCBs have been shown to be slightly more effective than beta blockers at lowering cardiovascular mortality, but they are associated with more side effects. Potential major risks however were mainly found to be associated with short-acting CCBs.
According to Mr Accuracy reports’s new survey, global Calcium Antagonists market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Calcium Antagonists market research.
Key manufacturers engaged in the Calcium Antagonists industry include Pfizer, Aventis, Searle, Bayer, AstraZeneca, Knoll Pharmaceuticals, Wyeth-Ayerst, Novartis and Sanofi, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Calcium Antagonists were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Calcium Antagonists market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Calcium Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
Novartis
Sanofi
Baiyunshan Pharmaceutical
South China Pharmaceutical Group
Tianjin Tanabe Seiyaku
Segment by Type
Dihydropyridine
Diltiazem
Verapamil
Others
Hypertension
Coronary Artery Disease
Arrhythmia
Ohers
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Calcium Antagonists report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents.
CCBs have been shown to be slightly more effective than beta blockers at lowering cardiovascular mortality, but they are associated with more side effects. Potential major risks however were mainly found to be associated with short-acting CCBs.
According to Mr Accuracy reports’s new survey, global Calcium Antagonists market is projected to reach US$ million in 2034, increasing from US$ million in 2024, with the CAGR of % during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Calcium Antagonists market research.
Key manufacturers engaged in the Calcium Antagonists industry include Pfizer, Aventis, Searle, Bayer, AstraZeneca, Knoll Pharmaceuticals, Wyeth-Ayerst, Novartis and Sanofi, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2024.
When refers to consumption region, % volume of Calcium Antagonists were sold to North America, Europe and Asia Pacific in 2024. Moreover, China, plays a key role in the whole Calcium Antagonists market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Calcium Antagonists market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Aventis
Searle
Bayer
AstraZeneca
Knoll Pharmaceuticals
Wyeth-Ayerst
Novartis
Sanofi
Baiyunshan Pharmaceutical
South China Pharmaceutical Group
Tianjin Tanabe Seiyaku
Segment by Type
Dihydropyridine
Diltiazem
Verapamil
Others
Segment by Application
Hypertension
Coronary Artery Disease
Arrhythmia
Ohers
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Calcium Antagonists report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices